Literature DB >> 24004350

Transient receptor potential melastatin 2: a novel target for treatment of gout.

Zhenyu Zhong1, Yougang Zhai, Liang Qiao.   

Abstract

Gout is an ancient autoinflammatory disease that affects millions of people worldwide. It is characterized by unbearable recurrent pain due to the massive local inflammation caused by the metabolic product, monosodium urate crystals. Although conventional therapies for gout can reduce the pain in patients, the severe undesirable side effects require the urgent need for novel therapies that can more specifically target gout-associated inflammatory pathways. Recent scientific advance on the mechanistic study of gout-associated inflammation is discussed and the potential of targeting the transient receptor potential melastatin 2 is highlighted as a novel therapeutic approach for the treatment of gout.

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 24004350      PMCID： PMC4106263          DOI： 10.1517/14728222.2013.835399

Source DB:  PubMed          Journal:  Expert Opin Ther Targets        ISSN： 1472-8222            Impact factor:   6.902


  30 in total

1.  Adenovirus type 5 rupture of lysosomes leads to cathepsin B-dependent mitochondrial stress and production of reactive oxygen species.

Authors:  Kathleen A McGuire; Arlene U Barlan; Tina M Griffin; Christopher M Wiethoff
Journal:  J Virol       Date:  2011-08-10       Impact factor: 5.103

Review 2.  The inflammasome: an integrated view.

Authors:  Olaf Gross; Christina J Thomas; Greta Guarda; Jurg Tschopp
Journal:  Immunol Rev       Date:  2011-09       Impact factor: 12.988

3.  Oxidized mitochondrial DNA activates the NLRP3 inflammasome during apoptosis.

Authors:  Kenichi Shimada; Timothy R Crother; Justin Karlin; Jargalsaikhan Dagvadorj; Norika Chiba; Shuang Chen; V Krishnan Ramanujan; Andrea J Wolf; Laurent Vergnes; David M Ojcius; Altan Rentsendorj; Mario Vargas; Candace Guerrero; Yinsheng Wang; Katherine A Fitzgerald; David M Underhill; Terrence Town; Moshe Arditi
Journal:  Immunity       Date:  2012-02-16       Impact factor: 31.745

4.  A role for mitochondria in NLRP3 inflammasome activation.

Authors:  Rongbin Zhou; Amir S Yazdi; Philippe Menu; Jürg Tschopp
Journal:  Nature       Date:  2010-12-01       Impact factor: 49.962

5.  Gout-associated uric acid crystals activate the NALP3 inflammasome.

Authors:  Fabio Martinon; Virginie Pétrilli; Annick Mayor; Aubry Tardivel; Jürg Tschopp
Journal:  Nature       Date:  2006-01-11       Impact factor: 49.962

Review 6.  Gout therapeutics: new drugs for an old disease.

Authors:  Christopher M Burns; Robert L Wortmann
Journal:  Lancet       Date:  2010-08-16       Impact factor: 79.321

Review 7.  New therapies for gout.

Authors:  Daria B Crittenden; Michael H Pillinger
Journal:  Annu Rev Med       Date:  2013       Impact factor: 13.739

Review 8.  New molecular mechanisms on the activation of TRPM2 channels by oxidative stress and ADP-ribose.

Authors:  Mustafa Naziroğlu
Journal:  Neurochem Res       Date:  2007-06-12       Impact factor: 3.996

9.  Silica crystals and aluminum salts activate the NALP3 inflammasome through phagosomal destabilization.

Authors:  Veit Hornung; Franz Bauernfeind; Annett Halle; Eivind O Samstad; Hajime Kono; Kenneth L Rock; Katherine A Fitzgerald; Eicke Latz
Journal:  Nat Immunol       Date:  2008-07-11       Impact factor: 25.606

Review 10.  Uric acid, hyperuricemia and vascular diseases.

Authors:  Ming Jin; Fan Yang; Irene Yang; Ying Yin; Jin Jun Luo; Hong Wang; Xiao-Feng Yang
Journal:  Front Biosci (Landmark Ed)       Date:  2012-01-01
View more
  1 in total

1.  Nickel induces interleukin-1β secretion via the NLRP3-ASC-caspase-1 pathway.

Authors:  Xiujin Li; Fei Zhong
Journal:  Inflammation       Date:  2014-04       Impact factor: 4.092
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.